Ergothioneine, blood exposure and subjective sleep quality

Editorial study summary

Study type

Human pharmacokinetic dose study and modelling, followed by a randomized, double-blind, placebo-controlled trial.

Product relevance

Relevant ingredient evidence on ergothioneine. The studied preparation and doses differ from the DR.MORGAN finished formulas.

Sample or population

Human participants in both studies. The abstract does not state the sample sizes.

Studied dose

Study 1: ergothioneine 5 or 10 mg/day. Study 2: ergothioneine 8 mg/day or placebo.

Duration

Study 1: 8 weeks. Study 2: 16 weeks.

Finding

The pharmacokinetic model estimated that 8 mg/day for 16 weeks would reach the target plasma concentration. In the second study, subjective sleep quality was better in the ergothioneine group than in the placebo group (p < 0.05).

Limitations

The abstract does not report sample sizes or objective sleep measures. The model estimate and subjective trial outcome cannot establish a sleep benefit for a DR.MORGAN product.

Study quality

The PubMed abstract was reviewed. Objective sleep outcomes and the full risk of bias could not be assessed from it.

Funding and disclosures

The publication discloses that several authors were employees of Suntory Global Innovation Center Ltd. Funding was not verified from the approved source material.

The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.

Reference

1. Estimation and Validation of an Effective Ergothioneine Dose for Improved Sleep Quality Using Physiologically Based Pharmacokinetic Model. Food Sci Nutr. 2025. DOI 10.1002/fsn3.70382. PMID 40475978